S3-Leitlinie Prostatakarzinom - AWMF
S3-Leitlinie Prostatakarzinom - AWMF
S3-Leitlinie Prostatakarzinom - AWMF
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
9. Literatur<br />
androgen-independent prostate cancer: a randomized phase II study. Eur Urol<br />
2007;52(6):1691-8. http://www.ncbi.nlm.nih.gov/pubmed/17306441<br />
372. Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systematic overview of radiation therapy<br />
effects in skeletal metastases. Acta Oncol 2003;42(5-6):620-33.<br />
http://www.ncbi.nlm.nih.gov/pubmed/14596519<br />
373. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful<br />
bone metastasis-a systemic review. Radiother Oncol 2005;75(3):258-70.<br />
http://www.ncbi.nlm.nih.gov/pubmed/16299924<br />
374. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate<br />
cancer. Cochrane Database Syst Rev 2006;(4):CD006250.<br />
http://www.ncbi.nlm.nih.gov/pubmed/17054286<br />
375. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M,<br />
Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for<br />
treatment of bone metastases in men with castration-resistant prostate cancer: a<br />
randomised, double-blind study. Lancet 2011;377(9768):813-22.<br />
http://www.ncbi.nlm.nih.gov/pubmed/21353695<br />
376. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in<br />
advanced prostate cancer. Clin Prostate Cancer 2005;4(1):31-7.<br />
http://www.ncbi.nlm.nih.gov/pubmed/15992459<br />
377. Honnens de Lichtenberg M, Miskowiak J, Rolff H. Hormonal treatment of obstructed kidneys<br />
in patients with prostatic cancer. Br J Urol 1993;71(3):313-6.<br />
http://www.ncbi.nlm.nih.gov/pubmed/8477317<br />
378. Michigan S, Catalona WJ. Ureteral obstruction from prostatic carcinoma: response to<br />
endocrine and radiation therapy. J Urol 1977;118(5):733-8.<br />
http://www.ncbi.nlm.nih.gov/pubmed/916091<br />
379. Feng MI, Bellman GC, Shapiro CE. Management of ureteral obstruction secondary to pelvic<br />
malignancies. J Endourol 1999;13(7):521-4.<br />
http://www.ncbi.nlm.nih.gov/pubmed/10569528<br />
380. Yossepowitch O, Lifshitz DA, Dekel Y, Gross M, Keidar DM, Neuman M, Livne PM, Baniel J.<br />
Predicting the success of retrograde stenting for managing ureteral obstruction. J Urol<br />
2001;166(5):1746-9. http://www.ncbi.nlm.nih.gov/pubmed/11586215<br />
381. Ganatra AM, Loughlin KR. The management of malignant ureteral obstruction treated with<br />
ureteral stents. Journal of Urology 2005;174(6):2125-8.<br />
http://www.ncbi.nlm.nih.gov/pubmed/16280741<br />
382. Docimo SG, Dewolf WC. High failure rate of indwelling ureteral stents in patients with<br />
extrinsic obstruction: experience at 2 institutions. Journal of Urology 1989;142(2 Pt 1):277-<br />
9. http://www.ncbi.nlm.nih.gov/pubmed/2746744<br />
383. Harris MR, Speakman MJ. Nephrostomies in obstructive uropathy; how should hormone<br />
resistant prostate cancer patients be managed and can we predict who will benefit? Prostate<br />
Cancer Prostatic Dis 2006;9(1):42-4. http://www.ncbi.nlm.nih.gov/pubmed/16402089<br />
384. Vernia P, Fracasso PL, Casale V, Villotti G, Marcheggiano A, Stigliano V, Pinnaro P, Bagnardi<br />
V, Caprilli R. Topical butyrate for acute radiation proctitis: randomised, crossover trial.<br />
Lancet 2000;356(9237):1232-5. http://www.ncbi.nlm.nih.gov/pubmed/11072942<br />
385. Sanguineti G, Franzone P, Marcenaro M, Foppiano F, Vitale V. Sucralfate versus mesalazine<br />
versus hydrocortisone in the prevention of acute radiation proctitis during conformal<br />
© <strong>Leitlinie</strong>nprogramm Onkologie | <strong>S3</strong>-<strong>Leitlinie</strong> <strong>Prostatakarzinom</strong> | Version 2.0, 1. Aktualisierung 2011
Change language